“…Most recently, an established equinederived F(ab')2 antivenom marketed in Mexico, Antivipmyn™ (Instituto Bioclon), has undergone a successful phase II investigation, andit is now in phase III U.S. trials [8,9]. This antivenom is created using the venoms of two Central American snakes and two snakes indigenous to both Mexico and the United States [10]. The phase II trial was conducted at Tucson, Arizona, where rattlesnakes predominate, whereas the ongoing phase III trial involves a more geographically diverse range of study sites [8,9].…”